What is the difference between denied-party screening and sanctions screening?

Sanctions screening checks parties against sanctions lists such as OFAC. Denied-party or restricted-party screening is broader: it also covers export-control lists and, for pharmaceutical distribution, healthcare-specific lists like FDA debarment and OIG exclusion. Sanctions screening is one part of denied-party screening.

How often should denied-party lists be screened?

Screen new parties at onboarding, screen the consignee and ordering party at the point of each shipment against current lists, and re-screen active parties whenever the lists update, often weekly. Screening only at onboarding misses parties added to a list later.

Why is fuzzy matching used in denied-party screening?

Because names on the lists rarely match your records exactly, due to transliteration, aliases, word order, abbreviations and typos. Fuzzy matching, using techniques like edit distance and token overlap, catches near matches that an exact-match check would miss, then surfaces them for a human to adjudicate.

Does denied-party screening apply to clinical trials?

Yes. Clinical sites, investigators and service providers should be screened, and pharmaceutical screening specifically includes the FDA debarment list, which covers individuals debarred from working on drug applications, and the healthcare exclusion lists. A sanctions-only screen would not catch a debarred investigator.

Compliance18 July 2026 · 10 min read

Denied-Party Screening for Pharmaceutical Distribution: The Complete Guide

Most denied-party screening guidance is written for general exporters and stops at sanctions and export-control lists. Pharmaceutical distribution has a second, healthcare-specific layer that general trade-compliance tools miss entirely: the FDA debarment list, DEA registration status, and the healthcare exclusion lists. A company that screens a consignee against OFAC but ships to an FDA-debarred investigator, or pays an OIG-excluded provider, has a compliance failure that a sanctions-only screen would never catch. This guide sets out every list a pharmaceutical distributor should screen against, why fuzzy matching matters, when to screen, and what good screening looks like in a logistics workflow.

What denied-party screening is

Denied-party screening, also called restricted-party or sanctioned-party screening, is the process of checking every party to a transaction, the consignee, the ordering party, the end user and intermediaries, against published lists of people and organisations you are prohibited or restricted from dealing with. In pharmaceutical distribution the parties include clinical sites, investigators, distributors, wholesalers and the ultimate recipient of the material.

The lists a pharmaceutical distributor should screen against

The lists fall into three groups. General trade-compliance tools usually cover the first. The second and third are what make pharmaceutical screening different.

Sanctions and financial lists

OFAC Specially Designated Nationals (SDN) list, the primary US sanctions list of blocked persons and entities.
OFAC Consolidated list, covering additional non-SDN sanctions programmes.
EU consolidated sanctions list and the UK OFSI consolidated list for EU and UK measures.
UN Security Council Consolidated List for UN sanctions.

Export-control lists

BIS Entity List and Denied Persons List, US export-control restrictions that matter when the material or its technology is export-controlled.
National export-control lists in the other jurisdictions where you ship.

Healthcare-specific lists

FDA debarment list, individuals and firms debarred from working on drug applications, relevant to investigators and service providers.
DEA registration status, for handlers of controlled substances, where an invalid or revoked registration is disqualifying.
HHS OIG List of Excluded Individuals and Entities (LEIE) and the US System for Award Management (SAM) exclusions, for providers and entities excluded from federal healthcare programmes.

Why fuzzy matching matters

Names on these lists rarely match your records exactly. Transliteration, aliases, word order, abbreviations, middle names and simple typos all defeat an exact-match check. Effective screening uses fuzzy matching, techniques such as edit distance (Levenshtein) and token overlap, to catch near matches, then presents the likely hits for a human to adjudicate. Too loose and officers drown in false positives; too tight and a real match slips through. The balance, and the audit trail of how each hit was resolved, is the heart of good screening.

When to screen

Screening is not a one-time gate at onboarding. Lists change, often weekly, and a party that was clear last month may be listed today. Screen at three moments:

At onboarding, before a new party is approved.
At the point of shipment, so the consignee and ordering party are checked against the current lists for this specific movement.
On list updates, by re-screening active parties when the lists refresh, so a newly listed party is caught even without a new transaction.

What good screening looks like in a logistics workflow

Every party, every shipment. The consignee, ordering party and relevant intermediaries are screened at submission, not just the account holder at onboarding.
All relevant lists, refreshed. Sanctions, export-control and healthcare-specific lists, updated on a defined schedule.
Fuzzy matching with human adjudication. Near matches are surfaced with a score, and an officer clears or blocks with a recorded reason.
A hard gate, not a warning. A confirmed hit blocks the shipment from moving until it is resolved.
A full audit trail. Who screened, against which list versions, what matched, and how each hit was dispositioned, retained for inspection.

The cost of getting it wrong

The penalties for sanctions and export-control violations are effectively strict-liability and severe, reaching into the millions per violation, and they attach to the company regardless of intent. Healthcare exclusions carry their own consequences: dealing with a debarred or excluded party can invalidate the work and expose the company to enforcement. Screening is cheap. The failure is not.

Frequently asked questions

At minimum the OFAC SDN and Consolidated lists, the EU and UK OFSI consolidated lists, the UN Security Council list, and the BIS Entity and Denied Persons lists for export control. Pharmaceutical distributors should also screen healthcare-specific lists: the FDA debarment list, DEA registration status, and the HHS OIG and SAM exclusion lists.